LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Curemark LLC
Headquarters:
Rye, NY, United States
Website:
http://www.curemark.com
Year Founded:
2004
Status:
Private
BioCentury
|
Apr 14, 2023
Management Tracks
Editas names Reeve chair, adds Levy to board
Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more
Read More
BioCentury
|
Sep 23, 2022
Management Tracks
Third Rock’s Finer becomes Septerna’s full-time CEO
Plus Thieroff-Ekerdt to head clinical development at Cambrian and an update from Curemark
Read More
BioCentury
|
May 23, 2017
Regulation
Misalignment in autism
FDA workshop reveals diversity of priorities among autism patients, caregivers
Read More
BioCentury
|
Jul 20, 2015
Financial News
Curemark completes venture financing
Read More
BioCentury
|
May 25, 2015
Clinical News
CM-AT: Phase III started
Read More
BioCentury
|
Nov 11, 2013
Clinical News
CM-AT regulatory update
Read More
BioCentury
|
Nov 5, 2013
Company News
Curemark begins rolling NDA for autism product
Read More
BioCentury
|
Oct 14, 2013
Financial News
Curemark completes venture financing
Read More
BioCentury
|
Oct 9, 2013
Financial News
Curemark closes $18.5 million equity financing
Read More
BioCentury
|
Jul 23, 2012
Company News
Curemark management update
Read More
Items per page:
10
1 - 10 of 17